| |
| |
|
| Insider
Information: |
Akkaraju Srinivas |
| Relationship: |
|
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
19 |
|
| Direct
Shares |
3,961,226 |
|
|
Indirect Shares
|
37,470,445 |
|
|
| Direct
Value |
$19,952,606 |
|
|
|
Indirect Value
|
$413,420,042 |
|
|
| Total
Shares |
41,431,671 |
|
|
| Total
Value |
$433,372,648 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
5
|
3
|
|
Stock
price went up :
|
4
|
1
|
| Stock
price went down : |
1
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
4.0
|
4.0
|
| Percentage
Gain/Loss : |
 28.4%
|
 -84.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Pharmos Corp |
PARS |
Director |
|
0 |
2006-10-25 |
2,845,160 |
Premium* |
|
|
Seagen Inc |
SGEN |
Director |
2020-05-15 |
41,503 |
2008-09-22 |
600,559 |
Premium* |
|
|
Paratek Pharmaceuticals Inc |
PRTK |
Former 10% Beneficial ... |
2011-07-19 |
1,181,967 |
|
0 |
Premium* |
|
|
World Heart Corp |
WHRT |
10% Owner |
2012-08-02 |
0 |
2010-01-26 |
0 |
Premium* |
|
|
Icagen Inc |
ICGN |
|
2011-07-28 |
200,500 |
|
0 |
Premium* |
|
|
Synageva BioPharma Corp |
GEVA |
Former Director |
|
0 |
2012-06-27 |
1,026,832 |
Premium* |
|
|
Durata Therapeutics, Inc. |
DRTX |
10% Owner |
2012-07-24 |
0 |
2012-07-24 |
3,028,439 |
Premium* |
|
|
MEI Pharma Inc |
MEIP |
10% Owner |
2013-02-19 |
2,502,775 |
|
0 |
Premium* |
|
|
Zs Pharma, Inc. |
ZSPH |
Director |
2015-12-17 |
0 |
2014-06-23 |
609,455 |
Premium* |
|
|
aTyr Pharma Inc |
LIFE |
Former 10% Owner, Dire... |
2015-05-12 |
0 |
2015-05-12 |
1,866,126 |
Premium* |
|
|
Aravive Inc |
ARAV |
Director |
2019-12-02 |
31,815 |
2019-12-02 |
576,066 |
Premium* |
|
|
Syros Pharmaceuticals, Inc. |
SYRS |
Director |
2023-12-21 |
2,666 |
2023-12-21 |
1,786,427 |
Premium* |
|
|
Principia Biopharma Inc |
PRNB |
Director |
2018-09-18 |
0 |
2018-09-18 |
383,480 |
Premium* |
|
|
Chinook Therapeutics Inc |
KDNY |
Director |
2023-08-11 |
0 |
2023-08-11 |
0 |
Premium* |
|
|
Lenz Therapeutics |
LENZ |
10% Owner |
2021-06-29 |
0 |
2022-04-12 |
8,497,067 |
Premium* |
|
|
Scholar Rock Holding Corp |
SRRK |
Director, 10% Owner |
|
0 |
2023-10-16 |
6,788,609 |
Premium* |
|
|
Cargo Therapeutics, Inc. |
CRGX |
10% Owner |
|
0 |
2023-11-14 |
4,121,689 |
Premium* |
|
|
Mineralys Therapeutics, Inc. |
MLYS |
|
2024-02-12 |
0 |
2024-02-12 |
5,074,916 |
Premium* |
|
|
Vtv Therapeutics Inc. |
VTVT |
|
2024-02-27 |
0 |
2024-02-27 |
265,620 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
123 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 5 of 5
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| MLYS |
Mineralys Therapeutics, I... |
|
– • • |
2024-02-12 |
4 |
A |
$13.50 |
$7,499,993 |
I/I |
555,555 |
5,074,916 |
0 |
- |
|
| KDNY |
Chinook Therapeutics Inc |
Director |
– • – |
2022-05-27 |
4 |
B |
$14.00 |
$7,980,000 |
I/I |
570,000 |
5,161,888 |
2.1 |
% |
|
| ARAV |
Aravive Inc |
Director |
– • – |
2016-10-03 |
4 |
B |
$12.25 |
$7,000,005 |
I/I |
571,429 |
571,429 |
2.1 |
- |
|
| ARAV |
Aravive Inc |
Director |
– • – |
2017-03-24 |
4 |
B |
$12.25 |
$7,000,005 |
I/I |
571,429 |
571,429 |
2.1 |
- |
|
| SYRS |
Syros Pharmaceuticals, In... |
Director |
– • – |
2020-12-08 |
4 |
A |
$0.00 |
$0 |
I/I |
625,000 |
1,899,616 |
0 |
- |
|
| ARAV |
Aravive Inc |
Director |
– • – |
2018-06-06 |
4 |
B |
$1.74 |
$1,149,585 |
I/I |
660,681 |
2,234,732 |
2.1 |
- |
|
| CRGX |
Cargo Therapeutics, Inc. |
10% Owner |
– – • |
2023-11-14 |
4 |
B |
$15.00 |
$9,999,990 |
I/I |
666,666 |
4,121,689 |
1.5 |
- |
|
| SYRS |
Syros Pharmaceuticals, In... |
Director |
– • – |
2022-09-16 |
4/A |
A |
$0.00 |
$0 |
I/I |
691,489 |
881,450 |
0 |
- |
|
| DRTX |
Durata Therapeutics, Inc. |
10% Owner |
– – • |
2012-07-24 |
4 |
B |
$9.00 |
$7,058,817 |
I/I |
784,313 |
3,028,439 |
1.5 |
- |
|
| SYRS |
Syros Pharmaceuticals, In... |
Director |
– • – |
2023-12-21 |
4 |
B |
$4.42 |
$3,999,998 |
I/I |
904,977 |
1,786,427 |
2.1 |
% |
|
| KDNY |
Chinook Therapeutics Inc |
Director |
– • – |
2021-11-15 |
4 |
B |
$14.00 |
$17,010,000 |
I/I |
1,215,000 |
4,591,888 |
2.1 |
% |
|
| LIFE |
aTyr Pharma Inc |
Former 10% Owner |
– • – |
2015-05-12 |
4 |
A |
$0.00 |
$0 |
I/I |
1,546,126 |
1,546,126 |
0 |
- |
|
| SGEN |
Seagen Inc |
Director |
– • – |
2007-02-09 |
4 |
S |
$8.57 |
$17,268,550 |
I/I |
(2,015,000) |
0 |
0 |
- |
|
| SGEN |
Seagen Inc |
Director |
– • – |
2007-02-09 |
4 |
A |
$0.00 |
$0 |
I/I |
2,015,139 |
94,520 |
0 |
- |
|
| SRRK |
Scholar Rock Holding Corp |
Director |
– • • |
2023-10-16 |
4 |
B |
$6.85 |
$15,000,000 |
I/I |
2,189,781 |
6,788,609 |
2.25 |
% |
|
| DRTX |
Durata Therapeutics, Inc. |
10% Owner |
– – • |
2012-07-24 |
4 |
A |
$0.00 |
$0 |
I/I |
2,244,126 |
2,244,126 |
0 |
- |
|
| WHRT |
World Heart Corp |
10% Owner |
– – • |
2010-10-19 |
4 |
B |
$2.14 |
$4,999,999 |
D/D |
2,341,920 |
6,063,603 |
2.45 |
- |
|
| KDNY |
Chinook Therapeutics Inc |
Director |
– • – |
2020-10-05 |
4 |
A |
$0.00 |
$0 |
I/I |
3,168,388 |
3,168,388 |
0 |
- |
|
| CRGX |
Cargo Therapeutics, Inc. |
10% Owner |
– – • |
2023-11-14 |
4 |
A |
$0.00 |
$0 |
I/I |
3,381,323 |
3,455,023 |
0 |
- |
|
| SGEN |
Seagen Inc |
Director |
– • – |
2007-07-09 |
4 |
A |
$0.00 |
$0 |
I/I |
4,485,000 |
1,058,640 |
0 |
- |
|
| KDNY |
Chinook Therapeutics Inc |
Director |
– • – |
2023-08-11 |
4 |
D |
$0.00 |
$0 |
I/I |
(5,161,888) |
0 |
0 |
- |
|
| WHRT |
World Heart Corp |
10% Owner |
– – • |
2012-08-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(6,063,603) |
0 |
0 |
- |
|
| LENZ |
Lenz Therapeutics |
10% Owner |
– – • |
2021-06-29 |
4 |
A |
$0.00 |
$0 |
I/I |
6,931,623 |
22,753 |
0 |
- |
|
123 Records found
|
|
Page 5 of 5 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
